Literature DB >> 27379978

4-Oxo-1,4-dihydroquinoline-3-carboxamide Derivatives as New Axl Kinase Inhibitors.

Li Tan1,2, Zhang Zhang1,3, Donglin Gao1,2, Jinfeng Luo1, Zheng-Chao Tu1, Zhengqiu Li3, Lijie Peng3, Xiaomei Ren1,3, Ke Ding1,3.   

Abstract

Axl is a new potential target for anticancer drug discovery. A series of 4-oxo-1,4-dihydroquinoline-3-carboxamides were designed and synthesized as highly potent Axl kinase inhibitors. One of the most promising compounds, 9im, tightly bound with Axl protein and potently inhibited its kinase function with a Kd value of 2.7 nM and an IC50 value of 4.0 nM, respectively, while was obviously less potent against most of the 403 wild-type kinases evaluated at a relatively high concentration. The compound dose-dependently inhibited the TGF-β1-induced epithelial-mesenchymal transition (EMT) and suppressed the migration and invasion of MDA-MB-231 breast cancer cells. In addition, 9im also demonstrated reasonable pharmacokinetics properties in rats and exhibited in vivo therapeutic effect on hepatic metastasis in a xenograft model of highly metastatic 4T1 murine breast cancer cells. Compound 9im may serve as a lead compound for new anticancer drug discovery and a valuable research probe for further biological investigation on Axl.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27379978     DOI: 10.1021/acs.jmedchem.6b00608

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  2 in total

1.  The Axl kinase domain in complex with a macrocyclic inhibitor offers first structural insights into an active TAM receptor kinase.

Authors:  Ketan S Gajiwala; Neil Grodsky; Ben Bolaños; Junli Feng; RoseAnn Ferre; Sergei Timofeevski; Meirong Xu; Brion W Murray; Ted W Johnson; Al Stewart
Journal:  J Biol Chem       Date:  2017-07-19       Impact factor: 5.157

2.  Discovery of JND3229 as a New EGFRC797S Mutant Inhibitor with In Vivo Monodrug Efficacy.

Authors:  Xiaoyun Lu; Tao Zhang; Su-Jie Zhu; Qiuju Xun; Lingjiang Tong; Xianglong Hu; Yan Li; Shingpan Chan; Yi Su; Yiming Sun; Yi Chen; Jian Ding; Cai-Hong Yun; Hua Xie; Ke Ding
Journal:  ACS Med Chem Lett       Date:  2018-10-08       Impact factor: 4.345

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.